Zacks: Analysts Anticipate Arbutus Biopharma Corp (NASDAQ:ABUS) to Announce -$0.35 EPS

Equities analysts expect Arbutus Biopharma Corp (NASDAQ:ABUS) to post earnings of ($0.35) per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Arbutus Biopharma’s earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.36). Arbutus Biopharma posted earnings per share of ($0.44) in the same quarter last year, which would suggest a positive year-over-year growth rate of 20.5%. The firm is scheduled to issue its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that Arbutus Biopharma will report full year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.78) to ($0.65). For the next year, analysts expect that the company will post earnings of ($1.09) per share, with EPS estimates ranging from ($1.57) to ($0.53). Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover Arbutus Biopharma.

Arbutus Biopharma (NASDAQ:ABUS) last released its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.16). Arbutus Biopharma had a negative return on equity of 95.26% and a negative net margin of 1,237.92%. The business had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $1.18 million.

ABUS has been the topic of a number of research reports. Chardan Capital reissued a “buy” rating and issued a $6.50 target price on shares of Arbutus Biopharma in a research note on Sunday, March 10th. BidaskClub raised shares of Arbutus Biopharma from a “hold” rating to a “buy” rating in a research note on Tuesday, March 5th. Zacks Investment Research raised shares of Arbutus Biopharma from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Tuesday, March 12th. Echelon Wealth Partners reissued a “hold” rating on shares of Arbutus Biopharma in a research note on Monday, March 11th. Finally, ValuEngine lowered shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. Arbutus Biopharma presently has an average rating of “Hold” and an average price target of $6.25.

ABUS traded down $0.14 during trading on Wednesday, reaching $2.28. The company’s stock had a trading volume of 24,417 shares, compared to its average volume of 673,445. The company has a current ratio of 12.75, a quick ratio of 12.75 and a debt-to-equity ratio of 0.06. The stock has a fifty day simple moving average of $2.00. Arbutus Biopharma has a 1 year low of $1.42 and a 1 year high of $12.60. The company has a market capitalization of $139.00 million, a P/E ratio of -2.26 and a beta of 1.84.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hudson Bay Capital Management LP lifted its stake in Arbutus Biopharma by 333.3% in the 4th quarter. Hudson Bay Capital Management LP now owns 650,000 shares of the biopharmaceutical company’s stock worth $2,490,000 after purchasing an additional 500,000 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Arbutus Biopharma by 219.9% during the 3rd quarter. Vanguard Group Inc. now owns 284,476 shares of the biopharmaceutical company’s stock valued at $2,688,000 after buying an additional 195,542 shares during the period. Bailard Inc. raised its position in shares of Arbutus Biopharma by 5.6% during the 1st quarter. Bailard Inc. now owns 228,000 shares of the biopharmaceutical company’s stock valued at $816,000 after buying an additional 12,000 shares during the period. Norges Bank purchased a new stake in shares of Arbutus Biopharma during the 4th quarter valued at approximately $1,416,000. Finally, Alps Advisors Inc. raised its position in shares of Arbutus Biopharma by 4.7% during the 1st quarter. Alps Advisors Inc. now owns 134,053 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 6,016 shares during the period. 41.76% of the stock is currently owned by institutional investors and hedge funds.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

Featured Article: Percentage Gainers

Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply